When cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman's pelvis (the area below your stomach and in between your hip bones). The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of your uterus, called the endometrium.
When uterine cancer is found early, treatment is most effective. The most common sign of uterine cancer is bleeding that is not normal for you because of when it happens or how heavy it is. This could mean bleeding, even a little bit, after you have gone through menopause; periods that are longer than seven days; bleeding between periods; or any other bleeding that is longer or heavier than is normal for you.
Other symptoms, such as pain or pressure in your pelvis, also may occur if you have uterine cancer. If you have any of these symptoms, talk to your doctor, nurse, or other health care professional right away. They may be caused by something other than cancer, but the only way to know is to see your health care professional.
A recently published paper in the journal Molecular Cancer by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Genetics Chairman at the University of Barcelona, shows that transfer RNAs for certain amino acids are altered at the epigenetic level in some types of cancer, expressing it in an exaggerated manner in some cases and being deficient in others.
No single gene causes uterine cancer, the fourth most common cancer among women, which is on the rise in the U.S.
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Scientists have largely been producing transcriptomic data in an attempt to find clues about modified cellular pathways that may be fueling cancer behavior.
The 1970s revealed the initial data indicating mutations in the genetic material of tumors, much before the first oncogene alterations were identified.
The cover for issue 29 of Oncotarget features Figure 5, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.
Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.